Mpox Is “Falling” in Africa—WHO’s New Report Says Don’t Trust the Curve
WHO Mpox SitRep 63: The “Decline” Comes With a Surveillance Warning
WHO Mpox Situation Report 63: Africa’s Case Decline Comes With a Surveillance Risk
The latest WHO multi-country mpox situation report provides a precise estimate of the outbreak's current status: tens of thousands of confirmed cases across Africa, with a trend line showing signs of easing.
On paper, this is “good news.” Weekly confirmed cases are down in key places, and the report notes fewer than 300 new confirmed cases per week recently.
But the risk question for Europe and the UK is not, “Are totals rising?” It says, “Where are cases being missed, and which transmission routes are still strong enough to export infections into connected networks?”
The story turns on whether declining confirmed cases reflect real transmission decline or shrinking detection capacity.
Key Points
WHO Situation Report 63 states that from 1 January 2025 to 15 February 2026, 30 African countries reported 45,726 confirmed mpox cases and 203 deaths (CFR 0.4%).
In the last six weeks covered by Report 63, 20 African countries reported 1,142 confirmed cases and 4 deaths (CFR 0.4%), with the highest recent totals in DRC (367), Madagascar (332), Guinea (104), Liberia (96), and Ghana (50).
Africa's cumulative confirmed cases increased by 1,184 and deaths increased by 5 compared to Situation Report 62 (data through 18 January 2026), while deaths over the last six weeks decreased from 5 to 4.
WHO explicitly warns that reduced surveillance activities in several countries may underestimate cases, and recent weeks are affected by reporting delays.
UKHSA reports 25 clade Ib cases in the UK up to 31 January 2026 and says the probability of importation has increased from medium to high due to wider person-to-person transmission outside Africa.
For Europe/UK, ECDC assesses moderate risk for MSM and low risk for the general population for clade Ib, with a “new pattern” emerging in countries outside Africa.
Mpox spreads primarily through close physical contact, including sexual contact, and it can also spread through household contact and contaminated materials.
In parts of Central and East Africa, zoonotic spillover from animals is also relevant.
Clade labels matter because they track transmission and uncertainty. The UK’s surveillance now separates clade Ib and clade IIb in official reporting, and UKHSA notes clade Ib importation risk has risen as person-to-person spread occurs outside Africa.
The UK’s mitigation posture is built around targeted vaccination for those at higher risk and post-exposure vaccination for close contacts, with an explicit commitment to expand eligibility if epidemiology changes.
The signal: what actually changed since Situation Report 62
Situation Report 62 (Africa data through January 18, 2026) reported 44,542 confirmed cases and 198 deaths across 29 countries, with 871 confirmed cases and five deaths in the prior six weeks.
Situation Report 63 (Africa data through 15 February 2026) reports 45,726 confirmed cases and 203 deaths across 30 countries, with 1,142 confirmed cases and 4 deaths in the prior six weeks.
That is a straightforward delta: +1,184 confirmed cases, +5 deaths, +1 reporting country, and +271 six-week confirmed cases, while six-week deaths decreased by 1.
The noise: why the “downtrend” can mislead decision-makers
WHO flags two classic distorters at once: reporting delays (recent weeks get revised upward later) and reduced surveillance activities (fewer tests and fewer detected cases).
So the most dangerous interpretation is a lazy one: "Cases are down; therefore, risk is down.” In a surveillance-limited environment, “down” can mean “not seen.”
Such an interpretation matters for Europe because export risk is shaped by what’s happening in the most connected pockets of transmission, not by continent-wide averages.
The constraint: transmission routes that still move cases into Europe
ECDC's threat reporting highlights that for both clade I and clade II, sexual contacts are important for spreading the disease, and Europe has already had clade I cases from people who have and haven't traveled.
That creates a practical constraint for policymakers: border measures do not stop network-driven spread if transmission becomes established inside sexual networks that cross borders frequently (travel, events, venue networks).
At the same time, ECDC still assesses risk as low for the general population in the EU/EEA, which implies the main near-term policy lever is targeted public health action, not broad population restrictions.
The hinge: the surveillance-and-testing gap that changes risk fastest
WHO’s key caution is that surveillance reductions may undercount cases.
Here’s the mechanism: if detection drops, reported incidence falls, but infectious people still travel. That widens the gap between “reported risk” and “real importation risk,” precisely the scenario that produces surprise clusters in highly connected networks.
This scenario is also why policy signals should lean more on testing intensity, positivity rates, and genomic surveillance coverage than on raw case totals when surveillance capacity is variable. WHO itself highlights genomic surveillance considerations in earlier recent reporting, and ECDC frames ongoing uncertainties around transmissibility and severity.
The test: the indicators that would confirm spillover risk for the UK
UKHSA reports 25 clade Ib cases in the UK up to 31 January 2026, mostly travel-linked, but also notes that person-to-person transmission outside Africa has changed the risk environment and increased the probability of importation.
What factors would operationally increase risk in the UK and Europe?
A rising share of cases without travel links (especially multiple unlinked cases).
Genomic evidence indicates clusters that align with local transmission, rather than recurrent importations.
Persistent detection in a small number of countries outside Africa that starts to look like a stable reservoir in connected networks.
What Most Coverage Misses
The key point is that if surveillance is shrinking faster than transmission, a declining confirmed-case curve can coexist with rising export risk.
Mechanism: as testing and field surveillance weaken, “cases” become a function of capacity, not just infection. Exportation then becomes less predictable, and Europe’s risk is driven more by detection gaps and network connectivity than by headline totals.
Two signposts that would confirm this hinge in the next weeks:
Countries reporting “downward trends" are also reporting lower testing volumes or operational constraints, alongside retrospective upward revisions.
In Europe and the UK, there have been more reports of cases with unclear or no travel links, accompanied by genomic clustering that suggests persistence.
What Happens Next
In the short term (next 24–72 hours to a few weeks), the policy-relevant question is whether the WHO-reported decline remains stable once delayed data lands, because delayed reporting can reshape the apparent direction of travel.
In the medium term (weeks to months), the risk in Europe and the UK changes if clade I transmission starts to happen more regularly outside of Africa in closely linked groups, as this raises the overall chance of exposure even without traveling to Africa.
For vaccination and travel behavior, the practical stance remains targeted: NHS guidance recommends mpox vaccination for people at higher risk (especially GBMSM, which has a higher exposure risk) and for close contacts post-exposure.
Watch for specific decision points:
The UK is already publishing clade-specific updates through late winter 2026.
ECDC threat updates that reclassify transmission patterns or risk levels for priority groups.
WHO updates that indicate whether surveillance reductions are improving or worsening.
Real-World Impact
A sexual health clinic in a major city increases appointment slots for vaccination because demand rises when travel-linked cases are reported, even if national totals stay flat.
A hospital's infection prevention team updates triage prompts so rash illness plus recent travel or exposure triggers faster isolation and testing, reducing staff exposure risk.
An event organizer quietly boosts health messaging and partner outreach for high-contact venues because the operational risk is concentrated in specific networks, not the general public.
A traveler planning a longer stay with household contact in an affected area adjusts behavior more than a short-term traveler, reflecting official risk stratification that depends on exposure type, not just destination.
The UK/Europe risk fork: containment success vs. quiet establishment
Europe’s dilemma is not whether mpox exists—it does—but whether clade I becomes predictably “native” in certain connected networks, which would turn sporadic importation management into long-term routine control.
If surveillance is strong and targeted vaccination stays high, clusters can remain contained, and the risk stays concentrated.
If surveillance weakens while transmission quietly persists, Europe can stay in a low-headline, high-uncertainty phase where risk is not explosive but consistently reintroduced.
The signposts are measurable: travel links breaking, local clusters forming, and genomes showing persistence rather than repeated one-offs.
The historical significance of this moment is that mpox management is moving from emergency posture to durable, targeted control—where data quality becomes the decisive asset.
